Celsion Receives Fast Track Designation For ThermoDox® Development Program To Treat Primary Liver Cancer

Celsion Receives Fast Track Designation For ThermoDox® Development Program To Treat Primary Liver Cancer
Celsion Corporation (Nasdaq: CLSN ), a leading oncology drug development company, today announced that the U.S. Food and Drug Administration (FDA) has designated the HEAT Study of its investigational drug, ThermoDox®, in combination with radiofrequency ablation (RFA), as a Fast Track Development Program.

Read more on PharmaceuticalOnline